Influence of prolactin on carcinogen-induced leukemogenesis in Long-Evans rats.
Hypophysectomy of rats bearing 7,12-dimethylbenzanthracene-induced leukemia has been reported to result in a prompt and persistent regression of the leukemia. The purpose of this study was to determine whether or not marked alterations in prolactin secretion would influence this neoplastic process. To determine this, immature male and female Long-Evans rats were divided into three groups: Group 1, controls; Group 2, pituitary grafted (hyperprolactinemia); and Group 3, 2-bromo-alpha-ergocryptine-treated (hypoprolactinemia). Two weeks after the initial treatment and at 2-week intervals thereafter (6 total), each rat was given a single intragastric intubation of 7,12-dimethylbenzanthracene (10 mg/rat). Two months after the initial carcinogen treatment and at 2- to 3-week intervals thereafter, all rats had liver biopsies for the identification of leukemia. Results clearly show that despite nearly 10-fold difference in mean serum prolactin levels in the three groups of female rats and nearly a 20-fold difference in the level of this hormone in male rats, no significant differences in the magnitude of this leukemogenic process could be detected. Thus, striking changes in prolactin secretion do not appear to influence significantly this leukemogenic process.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D001971:Bromocriptine; D005260:Female; D007942:Leukemia, Experimental / Q000139:chemically induced / Q000503:physiopathology*; D008297:Male; D010902:Pituitary Gland / Q000637:transplantation; D011388:Prolactin / Q000097:blood / Q000502:physiology*; D051381:Rats; D012737:Sex Factors; D014184:Transplantation, Homologous
D001971:Bromocriptine; D015127:9,10-Dimethyl-1,2-benzanthracene; D011388:Prolactin